Overview

Methylprednisolone Treatment of Friedreich Ataxia

Status:
Completed
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
This study will explore whether methylprednisolone treatment is safe, well-tolerated, and beneficial in patients that are diagnosed with Friedreich Ataxia (FRDA). The study will also explore if methylprednisolone has any effects on biomarkers associated with FRDA. All subjects in the study will receive the same steroid treatment.
Phase:
Early Phase 1
Details
Lead Sponsor:
Children's Hospital of Philadelphia
Collaborator:
Friedreich's Ataxia Research Alliance
Treatments:
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate